Margaretha F Warlé-van Herwaarden1, Aafke R Koffeman2, Vera E Valkhoff3, Geert W 't Jong3,4, Cornelis Kramers5, Miriam C Sturkenboom3,6, Peter A G M De Smet1,7. 1. Radboud University medical center, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, the Netherlands. 2. Department of General Practice, Erasmus MC University Medical Center, Rotterdam, the Netherlands. 3. Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, the Netherlands. 4. Children's Hospital Research Institute of Manitoba, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. 5. Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands. 6. Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. 7. Department of Clinical Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands.
Abstract
AIMS: Low-dose aspirin (LDA) and non-steroidal-anti-inflammatory drugs (NSAIDs) both increase the risk of upper gastrointestinal events (UGIEs). In the Netherlands, recommendations regarding the prescription of gastroprotective agents (GPAs) in LDA users were first issued in 2009 in the HARM-Wrestling consensus. National guidelines on gastroprotective strategies (GPSs) in NSAID users were issued in the first part of the preceding. The aim of the present study was to examine time-trends in GPSs in patients initiating LDA and those initiating NSAIDs between 2000 and 2012. METHODS: Within a large electronic primary healthcare database, two cohorts were selected: (i) patients newly prescribed LDA and (ii) patients newly prescribed NSAIDs between 2000 and 2012. Patients who had been prescribed a GPA in the previous six months were excluded. For both cohorts, patients' risk of a UGIE was classified as low, moderate or high, based on the HARM-Wrestling consensus, and the presence of an adequate GPSwas determined. RESULTS: A total of 37 578 patients were included in the LDA cohort and 352 025 patients in the NSAID cohort. In both cohorts, an increase in GPSs was observed over time, but prescription of GPAs was lower in the LDA cohort. By 2012, an adequate GPS was present in 31.8% of high-risk LDA initiators, vs. 48.0% of high-risk NSAID initiators. CONCLUSIONS: Despite a comparable risk of UGIEs, GPSs are prescribed less in high-risk LDA initiators than in high-risk NSAID initiators. For both groups of patients, there is still room for improvement in guideline adherence.
AIMS: Low-dose aspirin (LDA) and non-steroidal-anti-inflammatory drugs (NSAIDs) both increase the risk of upper gastrointestinal events (UGIEs). In the Netherlands, recommendations regarding the prescription of gastroprotective agents (GPAs) in LDA users were first issued in 2009 in the HARM-Wrestling consensus. National guidelines on gastroprotective strategies (GPSs) in NSAID users were issued in the first part of the preceding. The aim of the present study was to examine time-trends in GPSs in patients initiating LDA and those initiating NSAIDs between 2000 and 2012. METHODS: Within a large electronic primary healthcare database, two cohorts were selected: (i) patients newly prescribed LDA and (ii) patients newly prescribed NSAIDs between 2000 and 2012. Patients who had been prescribed a GPA in the previous six months were excluded. For both cohorts, patients' risk of a UGIE was classified as low, moderate or high, based on the HARM-Wrestling consensus, and the presence of an adequate GPSwas determined. RESULTS: A total of 37 578 patients were included in the LDA cohort and 352 025 patients in the NSAID cohort. In both cohorts, an increase in GPSs was observed over time, but prescription of GPAs was lower in the LDA cohort. By 2012, an adequate GPS was present in 31.8% of high-risk LDA initiators, vs. 48.0% of high-risk NSAID initiators. CONCLUSIONS: Despite a comparable risk of UGIEs, GPSs are prescribed less in high-risk LDA initiators than in high-risk NSAID initiators. For both groups of patients, there is still room for improvement in guideline adherence.
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Vera E Valkhoff; Miriam C J M Sturkenboom; Catherine Hill; Sander Veldhuyzen van Zanten; Ernst J Kuipers Journal: Can J Gastroenterol Date: 2013-03 Impact factor: 3.522
Authors: J van der Lei; J S Duisterhout; H P Westerhof; E van der Does; P V Cromme; W M Boon; J H van Bemmel Journal: Ann Intern Med Date: 1993-11-15 Impact factor: 25.391
Authors: N D Yeomans; A I Lanas; N J Talley; A B R Thomson; R Daneshjoo; B Eriksson; S Appelman-Eszczuk; G Långström; J Naesdal; P Serrano; M Singh; M M Skelly; C J Hawkey Journal: Aliment Pharmacol Ther Date: 2005-11-01 Impact factor: 8.171
Authors: Charles W Helsper; Hugo M Smeets; Mattijs E Numans; Mirjam J Knol; Arno W Hoes; Niek J de Wit Journal: Pharmacoepidemiol Drug Saf Date: 2009-09 Impact factor: 2.890
Authors: Hilda J I de Jong; Joke C Korevaar; Liset van Dijk; Eef Voogd; Christel E van Dijk; Martijn G H van Oijen Journal: BMJ Open Date: 2013-07-24 Impact factor: 2.692
Authors: Jay L Goldstein; David J Whellan; James M Scheiman; Byron L Cryer; Glenn M Eisen; Angel Lanas; John G Fort Journal: Cardiovasc Ther Date: 2016-04 Impact factor: 3.023
Authors: Richard Hunt; Leonid B Lazebnik; Yury C Marakhouski; Mircea Manuc; Ramesh Gn; Khin S Aye; Dmitry S Bordin; Natalia V Bakulina; Baurzhan S Iskakov; Abror A Khamraev; Yurii M Stepanov; Reidwaan Ally; Amit Garg Journal: Euroasian J Hepatogastroenterol Date: 2019-02-01
Authors: María Jesús Lallana; Cristina Feja; Isabel Aguilar-Palacio; Sara Malo; María José Rabanaque Journal: Int J Environ Res Public Health Date: 2018-08-24 Impact factor: 3.390